🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

518 results for “Cho” Clear

  1. Ursodeoxycholic acid

    Hospital Authority, Hong Kong

    Hepatitis D

    phase 2 small molecule active

    1 trial

  2. Ursodeoxycholic acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 small molecule completed

    1 trial

  3. Valbenazine Oral Capsule

    NEUROCRINE BIOSCIENCES INC

    Trichotillomania (Hair-Pulling Disorder)

    phase 2 small molecule active

    1 trial

  4. Volixibat

    Mirum Pharmaceuticals International B.V.

    Primary Biliary Cholangitis

    phase 2 small molecule active

    1 trial

  5. Volixibat

    Mirum Pharmaceuticals International B.V.

    Primary Sclerosing Cholangitis

    phase 2 small molecule active

    1 trial

  6. Volixibat

    Mirum Pharmaceuticals International B.V.

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule terminated

    1 trial

  7. Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 2 small molecule active

    1 trial

  8. Voxzogo 0.56 mg powder and solvent for solution for injection, powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 2 small molecule active

    1 trial

  9. Zercepac 150 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    cholangiocarcinoma or gallbladder carcinoma

    phase 2 small molecule active

    1 trial

  10. certepetide

    LISATA THERAPEUTICS, INC.

    Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  11. cladribine

    Ultragenyx UK Limited

    Cholangitis, Sclerosing

    phase 2 small molecule completed

    1 trial

  12. delolimogene mupadenorepvec

    Chongqing Precision Biotech Co., Ltd

    Malignant Melanoma

    phase 2 gene therapy completed

    1 trial

  13. donor-derived NK cell infusion

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

  14. dupilumab

    Regeneron UK Limited

    Allergic Bronchopulmonary Aspergillosis

    phase 2 small molecule completed

    1 trial

  15. elafibranor, Placebo of Elafibranor, elafibranor

    Ipsen

    Primary Sclerosing Cholangitis

    phase 2 small molecule active

    1 trial

  16. fluconazole

    Ultragenyx UK Limited

    Sporotrichosis

    phase 2 small molecule completed

    1 trial

  17. golexanolone

    COGNITION THERAPEUTICS INC

    Primary Biliary Cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  18. hydrocortisone

    Ultragenyx UK Limited

    Bronchopulmonary Dysplasia

    phase 2 small molecule completed

    1 trial

  19. ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab

    Second Affiliated Hospital of Soochow University

    Liver Cancer

    phase 2 small molecule active

    1 trial

  20. killed oral cholera vaccine

    International Peace Maternity and Child Health Hospital

    Cholera

    phase 2 mab completed

    1 trial

  21. low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  22. pCAR-19B cells

    Chongqing Precision Biotech Co., Ltd

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    2 trials

  23. self-expandable 125I radioactive seeds-loaded-stent

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cholangiocellular Carcinoma

    phase 2 other completed

    1 trial

  24. tauroursodeoxycholic acid (TUDCA)

    The First People's Hospital of Lianyungang

    Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources